Effects of gilteritinib: A Synthesis of Findings from 16 Studies

  1. Home
  2. Effects of gilteritinib
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of gilteritinib: A Synthesis of Findings from 16 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of gilteritinib: A Synthesis of Findings from 16 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major research findings

Gilteritinib is a new type of drug used to treat acute myeloid leukemia (AML) with mutations in the FLT3 gene. 13 、 16 、 1 、 3 、、 14 、 8 、 12 、 6 Research results show that Gilteritinib is effective in treating AML with FLT3-ITD mutations. 16 、 1 、 14 、 8 In addition, Gilteritinib has been shown to be effective in patients with relapsed or refractory FLT3-mutated AML after transplantation. 9 、 Gilteritinib shows higher selectivity and better efficacy compared to other FLT3 inhibitors. 2 、 11 However, Gilteritinib can cause side effects such as immune-related enteritis. 13 、 6 Also, Gilteritinib may interact with other drugs, so caution is required. 15 Gilteritinib is considered a promising drug for the treatment of AML as an FLT3 inhibitor, but its safety and efficacy need to be further investigated.

Benefits and risks

Benefits summary

Gilteritinib has been shown to be an effective drug for the treatment of acute myeloid leukemia (AML) with mutations in the FLT3 gene. 16 、 1 、 14 、 8 In addition, Gilteritinib has been shown to be effective in patients with relapsed or refractory FLT3-mutated AML after transplantation. 9 、 Gilteritinib shows higher selectivity and better efficacy compared to other FLT3 inhibitors. 2 、 11

Risks summary

Gilteritinib can cause side effects such as immune-related enteritis. 13 、 6 Also, Gilteritinib may interact with other drugs, so caution is required. 15

Comparison between studies

Common points of studies

All these studies suggest that Gilteritinib is an effective drug for the treatment of AML with FLT3 mutations.

Differences between studies

These studies differ in the methods of Gilteritinib administration, the patients involved, and the outcomes assessed. For example, 13 is a case report on the side effects of Gilteritinib, and 1 is a study that showed Gilteritinib to be effective in patients with relapsed or refractory FLT3-mutated AML after transplantation. 8 is a study that suggests that Gilteritinib may be effective in treating non-small cell lung cancer with ALK mutations.

Consistency and contradictions of results

These studies suggest that Gilteritinib is an effective drug for the treatment of AML with FLT3 mutations, but its safety and efficacy need to be further investigated. In particular, caution is needed as Gilteritinib can cause side effects such as immune-related enteritis. 13 、 6 Also, Gilteritinib may interact with other drugs, so caution is required. 15

Cautions for real-life application

Gilteritinib has been shown to be an effective drug for the treatment of AML with FLT3 mutations. 16 、 1 、 14 、 8 However, Gilteritinib can cause side effects such as immune-related enteritis. 13 、 6 Also, Gilteritinib may interact with other drugs, so caution is required. 15 It is important to use Gilteritinib according to the doctor’s instructions.

Limitations of current research

These studies suggest that further investigation is needed on the safety and efficacy of Gilteritinib. In particular, caution is needed as Gilteritinib can cause side effects such as immune-related enteritis. 13 、 6 Also, Gilteritinib may interact with other drugs, so caution is required. 15

Future research directions

Future research needs to further investigate the long-term safety and efficacy of Gilteritinib. In addition, research needs to be conducted on how to reduce the side effects of Gilteritinib.

Conclusion

Gilteritinib has been shown to be an effective drug for the treatment of AML with FLT3 mutations. 16 、 1 、 14 、 8 However, Gilteritinib can cause side effects such as immune-related enteritis. 13 、 6 Also, Gilteritinib may interact with other drugs, so caution is required. 15 It is important to use Gilteritinib according to the doctor’s instructions.

Literature analysis of 16 papers
Positive Content
14
Neutral Content
1
Negative Content
1
Article Type
0
0
0
3
16
2.

Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies.

Author: WeisbergEllen, MengChengcheng, CaseAbigail E, SattlerMartin, TivHong L, GokhalePrafulla C, BuhrlageSara J, LiuXiaoxi, YangJing, WangJinhua, GrayNathanael, StoneRichard M, AdamiaSophia, DubreuilPatrice, LetardSebastien, GriffinJames D

AML treatment
SM treatment

This article compares the in vitro activities of clinically available FLT3 and KIT inhibitors against cells expressing a variety of oncogenic FLT3 or KIT receptors, including wild-type (wt) FLT3, FLT3-internal tandem duplication (ITD), FLT3 D835Y, the resistance mutant FLT3-ITD+ F691L, KIT D816V, and KIT N822K. The results show a wide spectrum of activity of these various mutations to these clinically available TKIs.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

8.

Efficacy of gilteritinib in comparison with alectinib for the treatment of ALK-rearranged non-small cell lung cancer.

Author: AndoChihiro, IchiharaEiki, NishiTatsuya, MoritaAyako, HaraNaofumi, TakadaKenji, NakasukaTakamasa, WatanabeHiromi, KanoHirohisa, NishiiKazuya, MakimotoGo, KondoTakumi, NinomiyaKiichiro, FujiiMasanori, KuboToshio, OhashiKadoaki, MatsuokaKen-Ichi, HottaKatsuyuki, TabataMasahiro, MaedaYoshinobu, KiuraKatsuyuki

Improved antitumor efficacy
NK cell infiltration

This study investigated the effectiveness of gilteritinib, a multi-target tyrosine kinase inhibitor, against anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancers (NSCLC). The study found that gilteritinib was significantly more potent than alectinib, a standard ALK inhibitor, in inhibiting cell growth and tumor growth in both cell cultures and mouse models. Gilteritinib was also found to increase the production of interleukin-15 (IL-15), which may contribute to the drug's effectiveness by boosting the immune system.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

10.

Considering Sex and Gender in Therapeutics throughout the Product Life Cycle: A Narrative Review and Case Study of Gilteritinib.

Author: MaximosMira, BrabeteAndreea, LêMê-Linh, GreavesLorraine

Adverse drug effects
Drug dosing errors

This review discusses the importance of considering sex-related factors in clinical trial design and clinical decision-making, highlighting the need for more studies that clearly and objectively study and measure sex-disaggregated and sex-related outcomes.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

11.

PLM-101 is a novel and potent FLT3/RET inhibitor with less adverse effects in the treatment of acute myeloid leukemia.

Author: ChoiYong June, ParkJaewoo, ChoiHyoyi, OhSu-Jin, ParkJin-Hee, ParkMiso, KimJi Won, KimYoon-Gyoon, KimYong-Chul, KimMyung Jin, KangKeon Wook

FLT3/RET dual-targeting
PLM-101 anti-leukemic activity
Few adverse effects

This study introduces PLM-101, a new drug that targets both FLT3 and RET kinases, which are involved in acute myeloid leukemia (AML). PLM-101 showed potent anti-leukemic activity in vitro and in vivo, suggesting it could be a potential treatment option for AML.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

12.

Glasdegib for the treatment of acute myeloid leukemia.

Author: BruzzeseAntonella, MartinoEnrica Antonia, LabancaCaterina, MendicinoFrancesco, LuciaEugenio, OlivitoVirginia, FimognariFilippo, NeriAntonino, MorabitoFortunato, VignaErnesto, GentileMassimo

AML management advancement
Novel therapeutic options

Treatments for acute myeloid leukemia (AML) have improved over the past few years. New drugs like hypomethylating agents, Bcl2 inhibitors, FLT3 inhibitors, IDH1/2 inhibitors, and hedgehog pathway inhibitors have helped patients.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

13.

Gilteritinib-induced severe immune-related enteritis: a possible case report.

Author: LuoPan, QiuHuiying, YangYushan, WuJiaqi, SongXianmin, FanGuorong, LiuGaolin, GaoJunwei

Severe enteritis

This case report describes a patient with FLT3-mutated acute myeloid leukemia who developed severe immune-related enteritis while receiving gilteritinib for maintenance therapy. While the case suggests a possible link between gilteritinib and enteritis, further investigation is needed to confirm this association. This report emphasizes the need for vigilance in monitoring for potential adverse drug reactions associated with gilteritinib.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

14.

Patient-reported outcomes from the phase 3 ADMIRAL trial in patients with <i>FLT3</i>-mutated relapsed/refractory AML.

Author: RitchieEllen K, CellaDavid, FabbianoFrancesco, PigneuxArnaud, KandaYoshinobu, IvanescuCristina, PandyaBhavik J, ShahManasee V

Fatigue reduction

Patient-reported outcomes (PROs) can inform treatment selection and assess treatment value in acute myeloid leukemia (AML). This study evaluated PROs from the ADMIRAL trial in patients with FLT3-mutated relapsed/refractory (R/R) AML. The results showed that gilteritinib was associated with a favorable effect on fatigue and other PROs in patients with FLT3-mutated R/R AML.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

15.

Drug-drug interactions associated with FLT3 inhibitors for acute myeloblastic leukemia: current landscape.

Author: Solana-AltabellaAntonio, Megías-VericatJuan Eduardo, Ballesta-LópezOctavio, Martínez-CuadrónDavid, MontesinosPau

AML treatment
Drug interactions

FLT3 inhibitors (FLT3i) are drugs with limited experience and potential for drug-drug interactions (DDIs). This article highlights the risks associated with managing FLT3i DDIs in acute myeloid leukemia (AML) treatment and the importance of considering these interactions in complex patients.

ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

16.

Clinical Efficacies of FLT3 Inhibitors in Patients with Acute Myeloid Leukemia.

Author: SongMoo-Kon, ParkByeong-Bae, UhmJi-Eun

Improved AML outcomes

This review summarizes the role of FLT3 inhibitors in the treatment of acute myeloid leukemia (AML). It discusses the development of FLT3 inhibitors, their clinical efficacy, and ongoing research in frontline, relapsed/refractory, and post-transplant settings.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.